

**From:** Giordano, Erica  
**To:** [Patel, Manisha \(manisha.patel@novartis.com\)](mailto:Patel.Manisha@novartis.com)  
**Cc:** [Riggins, Cindy](mailto:Riggins.Cindy@novartis.com); [narin.ahmed@novartis.com](mailto:narin.ahmed@novartis.com)  
**Subject:** BL 125646 REMS Information  
**Date:** Friday, August 25, 2017 4:42:00 PM  
**Attachments:** [REMS \(Kymriah\) 23Aug.docx](#)  
[REMS Supporting Document \(Kymriah\) 23Aug.docx](#)  
[image001.png](#)

---

Good afternoon,

Please see the attached REMS and REMS supporting document and submit clean versions of each by responding directly to this e-mail by 9am Monday August 28, 2017 and follow-up by submitting the documents as an official amendment to the BLA by COB Monday August 28, 2017.

Please confirm receipt and let me know if you have any questions.

*Thank you,*

**Erica Giordano**

*Regulatory Project Manager*

Center for Biologics Evaluation and Research

Office of Tissues and Advanced Therapies

U.S. Food and Drug Administration

Tel: 240-402-8298

[Erica.Giordano@fda.hhs.gov](mailto:Erica.Giordano@fda.hhs.gov)



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."